Amneal Pharmaceuticals, Inc.

Thank you all for your patience. The conference call titled Amneal Pharmaceuticals Fourth Quarter and Full Year 2025 Earnings Call will begin shortly. During the presentation, you'll have the opportunity to ask a question by pressing star followed by the number one on your telephone keypads. Again, please stand by and we will begin in a few minutes. Thank you. Thank you. Good morning, and welcome to the Amniel Pharmaceuticals fourth quarter and full year 2025 earnings call. I'll now hand the call over to Amniel's head of investor relations, Tony DiMeo. Go ahead, please, sir.

Good morning, and thank you for joining Amniel Pharmaceuticals fourth quarter 2025 earnings call. Today, we issued a press release reporting Q4 results. The earnings press release and presentation are available at amniel.com. Certain statements made on this call regarding matters that are not historical flags, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the section entitled Cautionary Statements on Forward-Looking Statements for factors that may impact future performance. We also discussed non-GAAP measures, information on use of these measures and reconciliations to GAAP, are in the earnings release and presentation. On the call today are Chirag and Shintu Patel, co-founders and co-CEOs. Tasos Konideras, CFO. Our commercial leaders, Andy Boyer for Affordable Medicines, Joe Renda for Specialty, and Jason Daly, Chief Legal Officer. I will now hand the call over to Chirag.

Thank you, Tony, and good morning, everyone. 2025 was a defining year of excellent execution and portfolio expansion at MU. As a diversified biopharmaceutical company, across specialty, complex products, injectables, and biosimilars, we're building category leadership positions in large and growing markets. In 2025, revenue grew 8%, adjusted EBITDA increased 10%, Adjusted EPS rose 43%. 2025 marks our sixth consecutive year of growth. In our industry, that consistency of growth stands out. What's most exciting is not only what we have achieved so far, which we are truly proud of, but the even greater opportunity that lies ahead. We entered 2026 with a strong foundation and exciting strategic growth opportunities. Whether we are advancing the standard of care with innovative therapies like Crexon or expanding access to affordable complex medicines, our mission is clear, to become America's number one affordable medicines company. Since our founding over 20 years ago, MNIL has always been driven by the deep passion and responsibility to serve the millions of patients who rely on our medicines every day. And we're just getting started. Let me begin with our largest segment, affordable medicines. The business continues to grow year after year, driven by an expanding portfolio of complex, differentiated, and durable products. 2025 was an exceptional year for approvals and launches, particularly in complex generics and injectables. These launches are not one-time events. They are multi-year value drivers. As a result, we expect meaningful acceleration in our affordable medicine segment, revenue growth in 2026 and 2027. In injectables, we are executing with a clear ambition to become a top five player in the U.S. institutional market. Over the years, we have significantly expanded our R&D and manufacturing capabilities, adding the technical capabilities required for long-term leadership. Our strategy focuses on providing differentiated offerings for hospitals, including ready-to-use specialty injectables. With over 40 products and a pipeline of differentiated launches, we expect this business to scale substantially over time. In biosimilars, we're building a long-term growth engine. We begin with in-licensing and creating a strong commercial platform. In December, we received approval for our data biosimilars, our fourth and fifth products. With biosimilar Zola under review, we remain on track to have six biosimilars in the U.S. market by 2027. Strategically, our goal remains to be vertically integrated in biosimilars across development, manufacturing, and commercialization, which we believe is essential for long-term success. From a macro perspective, the opportunity is remarkable. Over the next decade, About 234 million of biologic cells will lose exclusivity, more than double the prior 10 years. And only about 10% of those products have biosimilars in development. This creates a significant long-term opportunity to dramatically expand patient access and drive very meaningful growth for our company. Next. In GLP-1, our cooperation with Pfizer is progressing well, and both teams are working together. We are here to assist Pfizer in a meaningful way. This initiative builds on what we do best, develop, manufacture, and commercialize complex medicines at scale, and position us to play a meaningful long-term role in one of the largest and fastest growing therapeutic categories in healthcare. Now, let's turn to the specialty segment. We're very pleased with the take of Crexon. At the end of 2025, about 23,000 patients were on therapy, reflecting over 3% market share one year post-launch. For context, Ryderi reached roughly 42,000 patients and 6% market share 10 years after launch. In December, interim phase four data reinforced that what physicians and patients are already seeing, Trexon delivers more good on time than other therapies. We remain confident in peak U.S. cells of 300 to 500 million for Trexon, which we believe is setting a new standard of care for Parkinson's patient. In the fourth quarter, we launched Brachia, first and only auto-injector for severe migraine and cluster headache patients. For many of these patients, the prior option was an emergency room visit. Rankia gives them control, delivering the same hospital medication in a ready-to-use auto-injector. Rankia is our next growth catalyst in specialty, with expected peak sales of $5,200 million. Lastly, Evcare continues to provide diversification and strategic advantage. Through government and distribution channels, Evcare strengthens our direct access to key end markets and provides an efficient path for new launches, including biosimilars, complex generics, and specialty products. Overall, we are building a diversified biopharmaceutical company that expands access and provides new therapies for patients and delivers consistent growth for investors. With that, I'll turn it over to Chintu.

Thank you, Chirag, and good morning. I will begin with gratitude and thank the global MNIL team for their dedication and hard work, which continue to drive our company's success. The formula for strong execution remains the same. Operational excellence robust innovation, and a differentiated portfolio. First on operations, our global manufacturing network and leading technical capabilities remain a core strategic advantage. We continually enhance efficiency through digitization, automation, and AI, which will drive cost efficiencies. In GLP-1s, our collaboration with Pfizer is progressing very well. Our manufacturing build-out of two new GLP-1 facilities remain on target, one for large-scale peptide production and one for advanced sterile field finish manufacturing designed to support all dosage forms. We are well positioned to participate meaningfully in the long-term GLP-1 market with this scalable and flexible manufacturing platform. In affordable medicine, We look to launch 20 to 30 new products each year. Importantly, it is not just the number of launches, but the value and complexity of these products that matter. In that regard, in 2025 was an exceptionally strong year. For years, we have strategically prioritized the development of complex generics, including injectables, ophthalmics, inhalation products, and other advanced drug device combinations. As a result, we are now in the midst of one of the most concentrated and impactful waves of high-value affordable medicine launches in MNIL's history. During the fourth quarter, we meaningfully expanded our portfolio with a series of important late 2025 approvals and launches across multiple areas. Highlights included Rasperidone extended release, our first long-acting injectable, sodium oxibate, vimatoprost, and cyclosporine in ophthalmics. The first generic for Iohexol and multiple other injectables for hospitals, including several epinephrine products. Notably, we also announced approval and now launching our first two inhalation products. baclomethazone, dipropionate, and albuterol sulfate. This reflects a decade of hard work by the team and marks our new entry into inhalation, which is new growth platform starting this year. With this level of activity, we are reaching an inflection point in complex innovation. Today, we have 59 ANDS pending with 64% classified as complex products and 52 more products in development with 94% complex. We look to file 10 to 15 key complex programs in 2026, including several more injectables and inhalation programs. This complex portfolio evolution positions us very well for sustainable growth. In biosimilars, we continue to build our business deliberately over time. Our next major milestone is biosimilar Zola, which represents our sixth potential biosimilar and our largest opportunity to date. Zola was one of the first blockbuster allergy biologics, and we expect to be among the first biosimilars in these over 4 billion U.S. market next year. We are very proud of the progress we have made in building a biosimilar business. As Chirag noted, we see a very significant opportunity ahead with the upcoming wave of biologic LOEs. Success in this space will require vertical integration from cell line development and R&D to manufacturing and commercial capabilities. That is what will be needed to be a long-term leader in biosimilar. In specialty, Kraxon continues to perform exceptionally well and believe it has the potential to become the standard of care for all people living with Parkinson's disease. For decades, the foundation of treatment has been immediate release, carbidopa, levodopa, a therapy that dates back to 1970s. IRCT-LD is limited by fluctuating symptom control, frequent dosing, and significant off time as the disease progresses. Crexant represents a meaningful advancement in therapy designed to address these long-lasting limitations by delivering more consistent symptom control with fewer daily doses. In 2024, we initiated a phase four real-world study of approximately 225 patients, converting them from rightary IRCD-LD and IRCD-LD with COMPT inhibitors to cracks on. In December, we shared the first interim results from this open-label study, which demonstrated clear and clinically meaningful differentiation. Patients treated with cracks on experienced substantially more good on time, less of time, and longer intervals of continuous good on time. Importantly, patients converted from IR to Kraxon showed over three hours more good on time per day, a result that is highly meaningful for Parkinson's patients. We look to generate further evidence to demonstrate Kraxon effectiveness and expect to share more data for 2026 and 2027. In addition, internationally, we have filed the products in a number of key countries, including India, Canada, and in Europe. Beyond Kraxon, we plan to expand our specialty portfolio over time with products in areas like CNS and others where differentiated delivery, real-world performance, and patient convenience matter. Brachia Autoinjector is a clear example, combining a proven therapy with differentiated drug delivery system that improves how patients receive care. specialty represents a multi-product growth engine for MNIL and will share more on our pipeline as it evolves. In summary, we are executing well, driving operational excellence, advancing innovation, and expanding a differentiated portfolio across affordable medicines, specialty, and biosimilar. The progress we made in Q4 reinforces our confidence in the path ahead With that, I will turn it over to Tasos.

Thank you, Chintu, and good morning, everyone. The fourth quarter completed another terrific year for MNIL with strong top and bottom line growth as Q4 revenues grew 11%, adjusted EBITDA grew 13%, and adjusted EPS grew 75%. Our consistent performance reflects our strategic choices relevancy of our broad portfolio, prudent capital allocation, and strong execution. In addition to strong top and bottom line growth, we also delivered strong full-year operating cost flow of $340 million, reduced net leverage to 3.5 times, and are successful refinancing extended maturities to 2032 and substantially reduced interest costs. So all in all, an excellent finish to the year. Over the next few minutes, I'll cover in more detail our fourth quarter and full year 2025 results and move on to our 2026 guidance. Starting with the fourth quarter, total company revenues grew 11% to a record $814 million. First, our affordable medicines segment was essentially flat to $437 million, reflecting the timing of key products and new launches. Second, specialty revenues were very strong again in Q4, up 38% year-over-year to $167 million due to strong demand across our key brands such as Crexan, Vitary, Unitroid, and some small initial sales of our newest branded product, Pre-K auto-injector for cluster headaches. Third, UpCare revenues grew 24% to $211 million, driven by strong growth in the government channel. Our Q4 revenues continued to benefit by approximately $50 million associated with one significant new product launch which accounted for approximately 100 million in new revenue for the full year 2025. Fourth quarter adjusted EBITDA of 175 million grew 13% driven by top line growth and limited operating expense growth. Q4 earnings per share of 21 cents grew 75% due to adjusted EBITDA growth and lower interest expense due to our favorable refinancing earlier in 2025. Let me now shift to our full-year 2025 performance, where we exceeded all our financial guidance metrics. Total company revenue of $3 billion increased 8%, driven by growth across all of our business segments as affordable medicines grew 4%, specialty grew 19%, and after grew 12%. We're also very pleased by the growth of our adjusted gross margin, which expanded by 50 basis points to approximately 43%. It's worth noting that Abcure's 2025 adjusted gross margin increased in excess of 400 basis points due to our concerted efforts to prioritize profitability. On the bottom line, full year 2025 adjusted EBITDA grew 10% to $688 million, and adjusted EPS grew 43% to $0.83. In addition to our strong financial performance in 2025, we feel great about the actions we have taken to strengthen our balance sheet. First, we have reduced net leverage from 7.4 times in 2019 3.9 times at the end of 2024, and finally to 3.5 times at the end of 2025. Second, we fully refinanced our debt last summer, and in January of this year, we repriced our term loan B to further lower interest rate expense. As a result, our weighted average cost of debt is down from 10% in 2024 to about 6.8% in 2026, and maturities have been extended out to 2032. Accordingly, interest expense in 2025 was 217 million compared to 256 million in 2024, and as importantly, we expect a further reduction in 2026. I'll now turn to our full year 2026 guidance, which in summary reflects another year of growth across all financial metrics. In summary, we expect upline growth between 1 and 4 percent, adjusted EBITDA growth between 5 and 10 percent, and adjusted EPS growth between 12 and 24 percent. Let me provide a bit more detail on each of our guidance metrics, starting with total company revenue of $3.5 billion to $3.15 billion, up 1% to 4%, as I mentioned. We expect the growth to be driven by our largest business segment, affordable medicines, where we expect growth between 7% and 8%. This is an acceleration from 4% growth in 2025 but in line with our prior three-year average. Our growth expectation is rooted in the robust cadence of new product launches we received from the FDA the last couple of months. As a result, we're entering 2026 with the highest number of product approvals, which de-risks our growth expectations. In our specialty segment, we expect 2026 revenues to be about flat to 2025, This temporary poison growth simply reflects the continued growth of Kraxan and our other brands being upset by the expected generic erosion of Raitari. As we look forward to 2027 and beyond, we expect our specialty business to resume its strong growth trajectory as the growth of Kraxan and our multiple other branded products overcome the loss of exclusivity of Raitari. In our out-of-care segment, we expect revenue between $625 million to $700 million in 2026, compared to $745 million in 2025 and $663 million in 2024. While the year-over-year revenues will be down in 2026, our expected profitability is flat year-over-year as we continue our successful efforts to focus on the more profitable segments of the business. For some of the newer audience on our call, it's worth noting that it has been about six years since we acquired 65% of Upcare, and over that time, top and bottom line have increased by over three times. very excited about Upcare's growth potential, given the strong fundamentals of expanding population of more than 20 million veterans and federal government workers, as well as the growing portfolio of new launches, such as biosimilars, complex generics, and specialty products. Overall, Upcare remains a highly strategic direct platform for Amniel, and we expect it to continue generating substantial profits and cash flow over time. Moving down the P&L, we expect 2026 adjusted gross margins of over 44%, which reflects approximately 100 basis points of gross margin expansion driven by the continued mixed shift in our business as the higher margin parts of our business are growing faster. As a result, we expect 2026 adjusted EBITDA between 720 and 760 million, up between 5% and 10%. From an EPS perspective, we expect 2026 adjusted EPS between $0.93 and $1.03, which reflects 12% to 20% earnings growth driven by strong adjusted EBITDA growth and lower interest expense. Now, in terms of quarterly phases for 2026, We expect a gradual build over the year for a couple reasons. First, the revenue associated with many new affordable medicines launches, as well as correction, will build throughout the year. And second, some launch-related investments are more front-end loaded to support key launches, such as a brachia autoinjector. Moving on to cash, we expect robust 2026 operating cash flow between $325 million to 375 million compared to approximately 340 million in 2025. And capex of approximately 110 million or 3% of revenue. Lastly, we're pleased to be added to the S&P small cap 600 index a month ago, which reinforces the consistency of our operating and financial performance over time. We believe this inclusion enhances our visibility with the investment community and continued expansion of our institutional investor base. In summary, we entered 2026 in our strongest position yet and with the wind in our backs. We expect sustained top and bottom line growth supported by our diversified portfolio and multiple growth drivers, including new branded launches such as correction and brachia, new biosimilar launches, and a very strong wave of new affordable medicines. Combined with our disciplined focus on profitable growth, operating efficiencies, and strong balance sheet, we see a clear path for substantial value creation. With that, I'll turn the call back to Chirag.

Thank you, Tasos. Our strong 2025 results and 2026 guidance reflect the momentum across our diversified business. We remain focused on the discipline execution of our strategy as we progress towards becoming America's leading affordable medicines company. Let's now open the call for Q&A.

Thank you. As a reminder for our audience, if you would like to ask a question, you may do so by pressing star followed by the number one on your telephone keypads. Again, that is star followed by the number one on your telephone keypads, please. And we now have our first question here from Chris Schott from J.P. Morgan. Go ahead, please. Your line is now open.

Great. Thanks so much for the questions, and congrats on all the progress. Maybe just to start out on CorrectZone, Post the Phase 4 data for the product, can you just elaborate a little bit more on the response you're seeing in the market from these results? And maybe as part of that, as we think about 2026, how should we think about either revenue or market share targets for the product? I just had one follow-up after that.

Excellent. Well, I'll start and have my brother add it on to this as well. So the phase four, it's interim result showing 3.13 hours of good on time, which is what we've been hearing from physicians and the experience of patient. So it's a huge uptake. 80% of the IR patient are converting to Crexon. And the phase four continues. Chintu will give more details on it. And we also have another study, which he will share as well. Market share, we would double it in 26, more than double the revenue. And as we march towards the first goal is to reach 100,000 patients, and second goal post will be to reach 200,000 patients. Reminding you, total is 700,000 patients on CDLD treatment. Chintu, why don't you add more on the clinical studies, please?

Yeah, hi, Chris. Good morning. So we are very excited about our interim results, which we will share for 50 patients. Throughout 26 and early 27, we will be sharing remainder, which is the total study was about 225 patients. And the data is looking pretty promising. And we have done, as I mentioned, converting patients first time from, you know, different therapy, not on just the IAR CDLD. We have done conversion from the RITERI, from IR with Compton inhibitor, and Kraxon is clearly showing substantial benefits of good on time compared to all those therapies. So we are very excited. We have a lot more data coming, and I think that will further enhance Kraxon's position in the market. Plus, we are looking at another phase four. At the right time, we will also disclose that phase four, which continue to generate the And what we are excited about is the difference it's making in patient lives. And that makes we have so many testimonials from the patient and the doctors. So I think when the product is doing well, obviously it will reflect in the cells and the revenue and uptake. So we are very pleased and a lot more coming in 26 and 27 with new data.

Great. Thanks so much. I just want maybe a quick follow-up on just on healthcare. I just want to make sure I'm understanding the 2026 guidance relative to 2025. So can you just talk a little bit more about the growth you're expecting in that kind of higher margin government channel versus the distribution business and just like roughly what type of gross margins we can think about kind of for that franchise for the year?

Thank you. Yeah, I can take that, Chris. Good morning. This is Tasos. Yeah, as I mentioned before, kind of stepping back, right? This business, when we acquired 65% of Obavcare, since then we have more than tripled the revenue, gross margins, and EBITDA. So it's great because we were able to leverage both the unique assets Emil brought to the transaction as well as the inherent growth in that business. So as we talked about, so when you look at 2025 versus 2024, right? So in 2025, the total revenue of AdCare was about $745 million. And in 2024, the revenue was $663 million. So that grew about total about 12%. About 50% of the revenue is between, about 40% of the revenue kind of goes into the government channel, 60% of the revenue goes in the distribution channel. So when you think about this 12% growth 2025 versus 2024, distribution, the distribution part of the business declined, okay, while the government business grew, okay? And the distribution declined, it was purposefully. done because that's what we talked about it because we decided to not chase businesses with one or two gross margin okay so as a result of that kind of what i would say is pivoting right um into into the kind of leaning hard into the government channel the gross margin of our Avcare business grew over 400 basis points. So the gross margin in 2025 of Avcare was 147 million compared to about 100 million in 2024. And the operating income in 2025 was 94 million compared to 57. So essentially, 25 versus 24, revenue up 12, gross margin up 41, operating income up 65. So great, great performance. So now as we look into 2026, there's two things that are happening. We continue to expect the distribution business to be declining, but because it's such a low profitability part of the business, it doesn't hit the bottom line. The government business is going to be down slightly, not because of anything fundamental that is happening, but in 2025 with such an extraordinary growth because we had this one generic product, essentially generic interest zone. that essentially were the only ones in the market. That product had $100 million worth of revenue, as I mentioned before, in 2025. In 2026, as it always happens, it will have some additional competition. So that's why in 2026, revenues declining is down because of our pivot away from distribution, number one. and not having that exclusivity, if you want to call that, of generic interest or impacting the government business as well. So that's what's going to drive the decline and what we like to call it almost like a reset level, reset level for 2026. But the bottom line is not going to be impacted because for a couple of reasons. A, there is other more profitable parts of the business who will be allocating resources, who will also be laying on some of the operating expenses. So these are the dynamics that are happening in NavCare, which essentially creates this reset revenue in 2026 before we resume top line and bottom line growth in 2027 and beyond. So I know I said a lot, Chris. Let me know if that was helpful.

That was perfect. Thank you so much. Appreciate it.

Thank you for that question, Chris. Moving on, we now have Matt Bellatore from Goldman Sachs. Go ahead, please. Your line is now open.

Great. Good morning, guys, and thanks for the question. Maybe on the Pfizer GLP-1 obesity partnership, Could you just share your latest update on the status of that partnership? And then how should we think about potential outcomes? For example, if they do end up buying you out, would that be a complete return of all rights and economics? Or are there other scenarios where, for instance, maybe you don't manufacture for a developed market, but you keep emerging market rights? And then if it is a complete buyout, what would be the plan for the new facilities in India? and the cash you would receive. I had one follow-up. Thank you.

So good morning, Nate. With Pfizer, our collaborations continue such as we had it with Medcera. Both teams are working together. Facilities actually accelerated in manufacturing. And we, several levels of C-levels meetings have been already conducted with Pfizer. So we expect nothing much to change. Right now, it's all waiting for the starting the phase three and getting the products and you know the demand is global and we have built a building such a remarkable highly automated fill and finish facility with latest and greatest equipment so Pfizer is very excited about that and also we are making great progress on our peptide manufacturing which you know is in the shortages with solid phase technology. And we're also introducing hybrid in the future. So our teams are working with Pfizer on those aspects as well. And we continue to have the marketing rights for 18 countries, including India and Southeast Asia. So we're excited about the entire partnership. And there are no plans to think about right now. It's moving great.

Okay, awesome. That's exciting. And then maybe just on business development, could you share your latest thoughts on strategy, areas of interest and capacity, and then how you're thinking about the potential vertical integration of biosimilars?

Yeah. So as we've been saying it since last couple of years, time is now to do the vertical integration. But similar opportunities are awesome. Regulatory is streamlined. And we are very familiar with the market. So very excited. That's where the capital allocation will go first. And then, as I said previously, 2027 and onward will be more focused on specialty assets. and keep building our pipeline there. Remember, organically, we are very strong in our R&D pipeline, so we keep our pipeline pool, more complex products, great team in-house we have, so we'll continue to invest in our own R&D, our own CapEx, which is strategically we've been investing and very excited about the future. And next five years is going to be tremendous growth than what we have even witnessed in the last five years.

Great. Thank you.

Thank you, Matt. Thank you for that. Thank you for that question, Matt. Moving on, we now have David Amselen from Piper Sandler. Go ahead, please. Your line is now open.

Hey, thanks. So just a few for me. I wanted to get your thoughts on the generic OmniPAC opportunity and what has been built into your 26 expectations regarding that opportunity. Talk about barriers to competition, potential approval of additional strengths, and the extent to which you think that's going to be a limited competition product for the foreseeable future. So I know that's a bunch, but that's number one. And then secondly, I had a question on Zolaire. Kind of similar set of questions, but wanted to get your thoughts on the extent to which that could be a limited competition market. I believe there's only two or three others. So talk about how big of an opportunity that could be in 27 and beyond. Thank you.

Great. Thank you, David. On Iohexol, you know, the supply chain is complicated. They will be entering the market. GE has the huge market share, so we'll be making inroads. The hospitals we have spoken to, they're very excited. But expect that as a ramp up because of the difficulty in the supply chain. So over the years, as we introduce more strength it will pick up uh so great great achievement from our r d team and complexity of manufacturing both we have achieved so excited always over time on iohexol on zola uh very excited right now it's sultry on and us and 26 large market growing market Very well set about we expect 65% to 70% to go through the private label, which gives us immediate bump in the sales rather than ramp up our market share over one, two, three years. So exciting opportunity. And as you know, MNIL is well positioned to do business with these large buying groups as we have been doing business with them over 20 years. Great relationship. number one pipeline in the in the in the in the country for them and they appreciate our uh our high integrity the quality standards we have uh so we expect tremendous partnership with these private label uh side of the business which i expect about going forward would be almost 70 would go through private label which would make the biosimilar penetration very effective. It would not have to wait for three, four years to get to 30%, 40% market share. It would jump to higher market share immediately in year one. And 20%, 30% will continue on a buy-in bill, which we are well positioned as well. So very excited on solar as well. Shintu, you wanted to add anything on Iohexol?

Yeah, David, I actually had a question on additional strength. So by end of the year, we will have approval for the missing strength. So by end of the year, we'll have the entire OmniPAC, all the strength. It's a very large opportunity for us. We have been working on strengthening our supply chain and increasing our capacity. So 26, we will start, but 27 onward, it would be a meaningful revenue contribution. And for competition perspective, it is a tough product. Supply chain perspective, manufacturing, it's a unique bottle. So all those things put together, I think we don't foresee a lot of competition and multiple strengths. So we are very excited, and by end of the year, we'll have all the strengths approved.

Okay, great. That's very helpful. Thank you.

Thank you, David. Moving on, we now have Les Salewski from Tourist Securities. Go ahead, please. Your line is now open.

Good morning. Thank you for taking my questions. First one on Crexon. Can you quantify the persistence at perhaps month three or six versus your internal expectations and versus right carry? Any sort of signal around this continuation? And how should we think about the growth to net evolving as you brought in access? And what's kind of the steady state growth to net you're expecting at peak? And then second, on the DHE autoinjector, what's the early patient profile? Is it migraine versus clusters and the switches from prior DHE exposure versus naive? Thank you.

Thank you, Leslie. Good morning. Crexon versus dietary, obviously, Crexon is performing. Much better, as I said, it took almost 10 years to get to 6% market share. First year we have 3% market share, 23,000 patients on it. Testimonials are amazing and we We get letters at our office, written letters from patients. Physicians are so excited about the product as well, and now our aim is to make that a first-line therapy over time so no patient has to take the old Sinemet, which is giving them a lot of fluctuations every hour and a half, two hours. So this is clearly a seven, eight hours, a good on time every day. So amazing stories. No comparison with Rytory. It is, we're doubling or more than doubling market share this year. So we'll reach six plus percent this year, which would be above Rytory. And we learned something. on the pricing side we learned everything we had about 35 percent of patients could not fill that prescription due to the pricing on a dietary we have uh really worked on it and have us put the pricing out there that that number has been reduced now and our gross tonight runs typical in this category about 40 to 45 percent uh but very excited about texan break here joe you want to uh it is also the break is for cluster headache as well as severe migraine so we're treating two segments and early excitement is amazing uh jordan is here he just came back from our national sales meeting would you like to shed some light on sure yeah thanks so much for the question and yeah the

The response from the field team so far has been fantastic on both Crexon and Berkey Auto Injector because what we're seeing in the market from the key KOLs has been very favorable. I would say with regards to your question about Crexon with persistence and adherence, it continues to improve as we continue to see more and more patients coming. on the product. And right now, it's surpassing that of Rytari. And we anticipate to see that continue to go up because we're seeing patients return to therapy at a higher rate with Crexant than they did with Rytari. So that's been very favorable. With Brickia Auto Injector, our strategy has been to focus on the key migraine treatment centers across the United States and key KOLs. And the response has been beyond our expectations so far. So we've been very pleased. We're about 90 days into the launch. And having come back now from our sales and marketing meeting, our national meeting this week, I'm even more further convinced that we're going to continue to drive growth for both of those products. The team is trained and ready, and we're going to be executing this year. So excited about that. Thank you.

Thank you, Les. And checking the Q&A list now. And we are now all clear. And with that, I'll go ahead and hand it back to Shivraj Patel for some final remarks. Go ahead, please.

Well, thank you, everyone, for joining the call today. Have a great Friday and weekend. Thank you. Thanks, everyone. Thank you. Thanks, everyone.

Thank you, gentlemen. And this concludes today's call. Thank you all for joining. You may now disconnect your lines and have a great weekend.